Emerging Contaminants and Antimicrobial Resistance in Wastewater: Monitoring and Solutions from a approach Health approach (CERA-ONE)
· Funding agency: PIUNA PROGRAM ( research , University of Navarra)
· Principal investigators: Dr . Yasser Morera and Dr. Ana Isabel Vitas
· Amount awarded: 54 ,232 euros
· Dates: August 31, 2026, to August 31, 2029
Microbiota and Gestational Diabetes: Identification and Study of New Bacterial Postbiotics (GESTABIOTIC)
· Funding Agency: PIUNA PROGRAM ( research , University of Navarra)
· Principal researcher : Dr . Paula Aranaz
· researcher: Dr . Guillermo Martínez de Tejada
· Amount awarded: €57 ,581.60
· Dates: August 31, 2026, to August 31, 2029
Mechanisms and effects of new pharmacological therapies in ischemic stroke in diabetes: role of NOX5-mediated oxidative stress
· Funding agency: Carlos III Health Institute - Ministry of Economics and Competitiveness
· Principal researcher : Dr . Guillermo Zalba
· Start and end dates: 2026–2028
Epigenetic Regulation of Cardiac Fibrosis: Kat5 as a Target for the Treatment of Myocardial Infarction
· Funding agency: ERDF funds, Carlos III Health Institute
· Principal investigator: Dr . Beatriz Pelacho
· Start and end dates: 2026–2028
The Role of Oxidative Stress and the Effect of Sex on Stroke in Diabetes. New Pharmacological Treatments
· Funding agency: Government of Navarre. Health department
· Principal investigator: Dr . Guillermo Zalba
· Start and end dates: 2025–2028
Acetyltransferases as epigenetic targets: analysis of their potential as antifibrotic therapies in myocardial infarction
·Funding organization: SpanishSociety of Cardiology (SEC)
· Principal investigator: Dr . Beatriz Pelacho
· Start and end dates: 2025–2028
Advance research ( research ) on infectious diseases and antimicrobial resistance to ensure that we have research ecosystems and healthcare systems capable of diagnosing, preventing, and treating them
· Funding agency: StateAgency for research. ERDF funds
· Principal investigator: Dr . Tomás Maira Litrán
· Amount funded:UNAV 345,100 €
· Start and end dates: 2025–2028
Identification of fibrotic targets and sex-dependent biomarkers for prognostic and therapeutic purposes in myocardial infarction.
·Funding agency: Government of Navarre. Health department
· Principal investigator: Dr . Beatriz Pelacho
· Start and end dates: 2025–2027
Advancing safe vaccines against ovine brucellosis: efficacy of improved B. melitensis and B. ovis vaccine candidates and innovative in vitro models
· Officialreference letter : PID2023-146797OB-C31 (BruVac-Cell)
·Funding agency: Ministry of Science, Innovation, and Universities
· Principalresearcher : Dr. Raquel Conde-Álvarez
·Amount funded: UNAV 162,500€
·Start and end dates: 09/01/2024 – 08/31/2028
Multifunctional spray-on dressings for the treatment of cutaneous leishmaniasis
· Funding agency: Ministry of Science, Innovation, and Universities
· researcher Principal: Dr. Paul Nguewa
· Start and end dates: January 1, 2025–December 31, 2027.
Modulation of glial and immune system activity as a neuroprotective strategy in Parkinson's disease.
· Funding agency: State Agency for research, ERDF funds
· Principal Investigator: Dr. Marisol Aymerich
· Start and end dates: 2024–2027
PROJECT BIOGREENFOOD
· Funding source: Funded through the Government of Navarre’s 2024–2027 call for strategic projects under the “ research and development ” program
· researcher coordinator: Dr. Fermín Milagro (research center in Nutrition. BIOGREENFOOD)
· researcher manager Department: Dr. Guillermo Martínez de Tejada
· Start and end dates: 2024–2027.
Study of the fatty acid transporter CD36 in metabolic reprogramming and survival of diffuse large B-cell lymphoma (DLBCL).
· Funding agency: State Agency for research, ERDF funds
· researcher Principal: Dr. Sergio Roa.
· Start and end dates: 2024–2027.
THERAVLINFO: network transpyrenean advanced therapies in non-Hodgkin's lymphoma
· Funding source: ERDF, POCTEFA funds
· researcher Principal: Dr. Sergio Roa.
· Start and end dates: 2024–2026.
Targeted Nanomedicine to Reverse Fibrosis in Ischemic Cardiomyopathy
· Funding agency: State Agency for research
· Principal Investigator: Dr. Beatriz Pelacho
· Start and end dates: 2024–2026
REPRODIVAC - Next-generation vaccines and diagnostics to prevent livestock reproductive diseases with global implications
· Officialreference letter : 101060813
· Funding source: the European Union’s Horizon Europe research and innovation program
· researcher manager UNAV.: Dr. Raquel Conde-Álvarez
· Expected start and end dates: 2022–2027
EMERGENTcy. Diagnosis, elimination and prevention of antibiotics and other emerging contaminants, resistant bacteria and antibiotic resistance genes in the urban water cycle of the POCTEFA territory.
· Officialreference letter : EFA037/01 EMERGENTcy
· Funding source: European INTERREG V-A Spain-France-Andorra Program (POCTEFA 2021–2027).
· researcher coordinator: Dr. Jairo Gómez (NILSA)
· researcher manager UN: Dr. Ana Isabel Vitas
· Amount funded: 1,299,834 € (UN: 132,054 €)
· Start and end dates: January 1, 2024–June 30, 2027